71results about How to "High clinical value" patented technology

The invention relates to the technical field of biology, provides a stem cell transport protection solution and particularly relates to an adipose-derived mesenchymal stem cell transport protection solution suitable for long-distance transport. The stem cell transport protection solution is prepared from 10 to 30 percent DMSO (dimethyl sulfoxide), 50 to 150 mu g/mL streptomycin, a 50 to 80 percentDMEM (Dulbecco modified eagle medium) and 8 to 20 percent HES (hydroxyethyl starch). The adipose-derived mesenchymal stem cell transport protection solution has the advantages that the stability of cells and the activity of the cells may be maintained, and convenience is brought to storage and long-distance transport.

The invention discloses a nucleic acid aptamer for recognizing liver cancer cells, and a screening method and a purpose thereof. The nucleotide sequence of the nucleic acid aptamer comprises the feature sequence part shown as Seq ID No.1. The purpose comprises the purpose of the nucleic acid aptamer to the design and preparation of anti-liver-cancer medicine or detection reagents. The detection reagents comprise enzyme-linked immunosorbent assay, immunoradiometric assay or fluorescence method. The invention also comprises a target preparation and a medicine composition. The target preparationcomprises the nucleic acid aptamer and a medically acceptable carrier or a shaping agent. The medicine composition comprises the nucleic acid aptamer, at least one antitumor medicine and a medically acceptable carrier. Compared with the prior art, the nucleic acid aptamer can be used for specifically recognizing the liver cancer cells; good application prospects are realized.

The invention relates to the field of cell therapy. In particular, the present invention relates to modified mesenchymal stem cells and a culture supernatant thereof, and a pharmaceutical compositioncomprising the cells or the culture supernatant thereof. The invention also relates to the use of the modified mesenchymal stem cells and the culture supernatant for treatment of metabolic disorder ina subject (eg, a human) and the use of the modified mesenchymal stem cells in preparation of a medicine for treating the metabolic disorder in the subject (eg, a human). The invention further relatesto a method of treating the metabolic disorder, which comprises the step of administering to the subject in need thereof the modified mesenchymal stem cell or the culture supernatant or the pharmaceutical composition thereof.

The present invention relates to antibodies (particularly humanized antibodies) against hepatitis B surface antigen (HBsAg), nucleic acid molecules encoding the antibodies, methods for preparing the antibodies, and pharmaceutical compositions containing the antibodies. Furthermore, the invention relates to use of the antibodies and the pharmaceutical compositions. The antibodies and pharmaceuticalcompositions are useful for preventing and/or treating HBV infection or hepatitis B infection and related diseases (such as hepatitis B), for neutralizing the virulence of HBV in a subject (such as ahuman), or for reducing serum levels of HBV DNA and/or HBsAg in the subject.

The invention relates to an agonist of deacetylase and application thereof, and belongs to the technical field of medicines. The agonist of deacetylase comprises cinnamyl aldehyde, cinnamyl aldehyde structural analogues or cinnamyl aldehyde derivatives, wherein the cinnamyl aldehyde structural analogues comprises phenylpropionaldehyde, phenylacetaldehyde, benzaldehyde, propionaldehyde, acetaldehyde or formaldehyde; the cinnamyl aldehyde derivatives comprise alpha-bromo cinnamaldehyde, alpha-bromo p-chloro cinnamaldehyde, alpha-bromo p-methyl cinnamaldehyde, alpha-methyl cinnamaldehyde, alpha-hexylcinnamaldehyde, 4-chloro cinnamaldehyde, 4-methoxy cinnamaldehyde, 4-fluoro cinnamaldehyde, 2-nitro cinnamaldehyde and p-chloro cinnamaldehyde. The regulation effect of an ARG-NO pathway in a high-glucose induced endothelial cell injury model proves that the agonist of the deacetylase has a protective effect on vascular endothelial injury as an agonist of HDAC.

The invention relates to a method and a system for positioning three-dimensional locations of implants of bones and joints by the aid of structural features. The method includes carrying out earlier-stage processing on image data of bone and joint tissues of human bodies; building two-dimensional projection templates by the aid of projection features of imaging systems, structural feature points of the implants and anatomy feature points of the bones or the joints; solving and building mathematical mapping relations between three-dimensional models and the two-dimensional projection templates;computing and measuring the spatial locations of the implants. Mutual movement features and long-term biomechanics interaction of the three-dimensional models and the two-dimensional projection templates can be tracked by means of long-term follow-up visit. The system comprises modules for implementing various functions of the method. The method and the system have the advantages that accurate data with 6 degrees of freedom can be provided for positioning the surgical implants, and clinical values of domestic and overseas clinical two-dimensional image follow-up visit data can be increased.

The invention discloses a hip spica cast orthopedic bed with an adjustable angle, and is applicable to the technical field of medical apparatuses. The bed comprises a support plate and a leg dilating-pushing-supporting mechanism. The leg dilating-pushing-supporting mechanism is installed at the upper side of the support plate, and comprises a support rod detachably connected with a lifting support rack and a leg support cushion arranged at the end away from the support rod. The support rod is horizontally arranged at the top of the support plate with adjustable length. The hip spica cast orthopedic bed with the adjustable angle breaks through the shortcoming that the traditional gyp fixing operation mode is low in efficiency, costly in time and labor, big in human error factor influence, and thoroughly liberates the limitation of human labor resources. One person is enough to complete the treatment of the gyp-supported orthopedic fixing. The hip spica cast orthopedic bed with the adjustable angle has the advantages of being small in size, simple in operation, convenient to dismantle and install and carry, low is production cost, high in clinical value, and therefore worthy to be popularized with full force.

The invention relates to the field of therapeutic antibodies, in particular relates to an anti-programmed cell death-ligand 1 (PD-L1) antibody preparation. The preparation comprises an anti-PD-L1 antibody, a buffer solution and sodium chloride, and added sugar and/or sugar alcohols are absent. The anti-PD-L1 antibody preparation of the invention can maintain antibody stability after long-term storage. In addition, the invention further relates to a use of the anti-PD-L1 antibody preparation in preparing drugs used for the prevention and/or treatment and/or adjuvant treatment and/or diagnosis of tumors or anemia

The invention discloses an establishing method of a rat atrial fibrillation model for simulating characteristics of human diseases. The establishing method comprises the steps that 1) an experimentalrat is raised to 35-45 weeks; 2) for the experimental rat, overload of the rat heart pressure is induced by cervical transverse aortic constriction, and a TAC model rat is formed; 3) after the transverse aortic constriction is carried out on the TAC model rat for 1-2 weeks, small animal ultrasonic treatment is conducted to detect a two-dimensional ultrasonic image and color Doppler flow image of blood vessels of a constriction part; 4) after the TAC model rat is constructed for 6-9 weeks, the inner diameter of the left atrium is detected through small animal ultrasonic treatment, the myocardial metabolism is detected by adopting PET, and the occurrence of atrial remodeling is verified; 5) after the transverse aortic constriction is carried out on the TAC model rat for 6-9 weeks, atrial fibrillation is induced through esophageal electrostimulation, a bioelectrical signal recorder is used for recording an electrocardiogram of the experimental rat body surface, and the rat atrial fibrillation model is obtained through verification. The constructed rat atrial fibrillation model can reflect the characteristics of the clinical human diseases, and the establishing method is simpler, moreconvenient, more economical and more efficient.

The invention discloses a novel direct bilirubin detection kit. The novel direct bilirubin detection kit consists of a reagent R1 and a reagent R2, wherein the reagent R1 consists of a Tris-HCl tartaric acid sodium hydroxide buffer solution, glycerine, dithiothreitol, silver nitrate, methyl isobutyl ketone, triton X-100, Na2-EDTA and oxammonium hydrochloride; the reagent R2 consists of sodium hydrogen phosphate, sodium biphosphate, sodium persulfate, Na2-EDTA and NaCl. All the components are scientifically combined, the accuracy in measuring a sample within 0-400 [mu]mol/L is relatively good, the precision is high, the repeatability is good, the anti-interference ability is strong, the reagents are relatively good in stability, and the novel direct bilirubin detection kit is suitable for a full-automatic biochemical analyzer and has a high clinical use value.

The invention belongs to the field of biomedicine, and relates to a compound shown in a formula I, stereoisomers, mixtures or pharmaceutically-acceptable salts of the compound. The invention further relates to an application of the compound, stereoisomers, mixtures or pharmaceutically-acceptable salts thereof in preparing medicines for treating and/or preventing MERS-CoV infection or diseases related to MERS-CoV infection (such as Middle East respiratory syndrome). The formula is as below:(Z-Ile-Glu-X1-Ile-Val-Lys-Lys-Ile-X2-X3-Ile-Glu-Arg-Ala-Ile-Glu-Ala-Gln-Gln-X4-Leu-Leu-Gln-Leu-Thr-Val-Trp-X5-Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-B)n(I).

The invention relates to the fields of molecular biologics and disease treatment, in particular to the field of treatment on diseases related to too low activity of PSD-95 and/or PSD-93. Specifically,the invention relates to polypeptide (or variants thereof) for treating diseases related to too low activity of PSD-95 and/or PSD-93 (such as nervous system diseases), a fusion protein with the polypeptide (or variants thereof), and application of the polypeptide (or variants thereof) and the fusion protein. The invention further relates to a medicine composition for treating or alleviating one or more symptoms of diseases related to too low activity of PSD-95 and/or PSD-93 (such as nervous system diseases), wherein the medicine composition comprises the polypeptide (or variants thereof) or the fusion protein.

The invention provides an intelligent calculus detection system through a urinary system X-ray plain film. According to the intelligent calculus detection system through the urinary system X-ray plainfilm, after a patient completes a urinary system X-ray plain film examination item, an image recognition module recognizes a DICOM image matched with the examination item; an image quality judging module performs quality analysis and judgment on the DICOM image; a postoperative judging module performs postoperative change analysis on the DICOM image with qualified quality; an anatomy segmentationmodule performs target organ segmentation on the DICOM image without the postoperative change; a target focus inspection module performs segmentation and positioning on a focus; a structured reporting module integrates all processed data and images, stores the data and the images, and outputs a diagnosis image as the reference for a doctor; and a fully intelligent structured image diagnosis report is automatically generated. The invention also discloses an intelligent calculus detection method through a urinary system X-ray plain film. The system and the method provided by the invention havethe advantages that on the premise of ensuring the quality, the intelligent degree and the normativity are improved; the work efficiency of a community-level doctor is improved; the workload of the doctor is reduced; the work intensity is reduced; and the diagnosis precision is improved.

The invention relates to the fields of biotechnology and disease treatment, and in particular, relates to the field of thrombotic disease treatment. Specifically, the invention relates to a fusion protein comprising an anticoagulant protein and an immunoglobulin Fc structural domain, as well as a medical use of the fusion protein.

Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure of

Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.

The invention provides a novel humanized neutralizing active monoclonal antibody against novel coronavirus and application thereof. The monoclonal antibody with neutralizing activity is separated andscreened from the body of a rehabilitation patient infected with the novel coronavirus, has excellent affinity and specificity for the novel coronavirus (SARS-CoV-2), and can effectively block the combination of the novel coronavirus and receptor protein.

The invention belongs to the technical field of biological medicines, and particularly relates to an Orlistat inclusion compound and a preparation method and application thereof in antineoplastic medicines. The Orlistat inclusion compound disclosed by the invention is an Orlistat-sulfobutylether-beta-cyclodextrin inclusion compound, and the weight ratio of Orlistat to sulfobutylether-beta-cyclodextrin is 1:1-1:25. The invention prepares Orlistat into the inclusion compound, and sulfobutylether-beta-cyclodextrin can increase the solubility of Orlistat, enhance the stability of a medicine, promote medicine absorption and reduce the stimulation of the medicine to the body; as a carrier for Orlistat, sulfobutylether-beta-cyclodextrin can greatly improve the water solubility of guest molecules, so that Orlistat can be adapted to the requirement of liquid preparation and the bioavailability of Orlistat can be increased, and thereby the medicinal value of Orlistat can be better exerted; and the Orlistat inclusion compound can be used in the preparation of antineoplastic medicines, and has great potential clinical value.